Electromed price target raised to $26 from $20 at Lake Street

Lake Street analyst Brooks O’Neil raised the firm’s price target on Electromed to $26 from $20 and keeps a Buy rating on the shares after the company reported "strong" fiscal Q2 results that the firm points to as evidence of building momentum in the company’s strategic growth initiatives. Electromed, as "the only remaining pure-play competitor in what we believe is a large, established but underserved market," is "exceptionally well positioned for success going forward" with the limited release of its recently approved fifth generation SmartVest Clearway device, the firm tells investors.